PPA
VIRX

Parametric Portfolio Associates’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Parametric Portfolio Associates’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$115K Buy
+24,129
New +$72.7K ﹤0.01% 3543
2015
Q3 		– Sell
-222
Closed -$140K – 3342
2015
Q2 		$140K Sell
222
-6
-3% -$3.19K ﹤0.01% 3831
2015
Q1 		$117K Sell
228
-24
-10% -$12.1K ﹤0.01% 3842
2014
Q4 		$135K Sell
252
-43
-15% -$19.4K ﹤0.01% 3866
2014
Q3 		$443K Buy
295
+6
+2% +$8.69K ﹤0.01% 3267
2014
Q2 		$396K Buy
289
+45
+18% +$52.2K ﹤0.01% 3360
2014
Q1 		$338K Buy
244
+91
+59% +$106K ﹤0.01% 3379
2013
Q4 		$152K Buy
153
+3
+2% +$3.1K ﹤0.01% 3678
2013
Q3 		$156K Buy
+150
New +$160K ﹤0.01% 3659

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Parametric Portfolio Associates's VIRX Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2022: 24,129 shares worth $115K. The stake represents ﹤0.01% of the portfolio and ranks #3543 among its holdings. This is a return to the name: Parametric Portfolio Associates previously reported a position in VIRX as recently as Q2 2015.

Parametric Portfolio Associates first reported a position in VIRX in Q3 2013 and has held it in 9 quarters since. The position peaked at $443K in Q3 2014. 69 funds tracked by Wall St. Rank hold VIRX as of Q1 2022.

  • Parametric Portfolio Associates held 24,129 shares of Viracta Therapeutics, Inc. Common Stock worth $115K as of Q1 2022.
  • Viracta Therapeutics, Inc. Common Stock was a new Parametric Portfolio Associates position in Q1 2022.
  • Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3543 holding.
  • Parametric Portfolio Associates first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and has held it in 9 quarters since.
  • Parametric Portfolio Associates's Viracta Therapeutics, Inc. Common Stock position peaked at $443K in Q3 2014.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.